GRAIL Inc (GRAL)

On October 29, 2025, GRAIL announced it would report its Third Quarter 2025 Financial Results. On October 20, 2025, GRAIL, Inc. announced a $325.0 million private placement financing. Also on October 20, 2025, GRAIL and the University of Oxford were scheduled to present long-term data from the SYMPLIFY Study at the Early Detection of Cancer Conference (EDCC). On November 13, 2025, GRAIL Inc. filed its 10-Q, reporting a revenue increase to $36.2 million for the quarter, up from $28.7 million the previous year, despite a net loss of $88.9 million, an improvement from the previous year's $125.7 million loss. As of November 10, 2025, GRAIL's stock price was $85.11, with a market capitalization of $3.3 billion.

The provided information does not explicitly detail the demand seasonality for GRAIL, Inc.'s products and services. However, the company has seen increasing repeat test volumes for its Galleri test, with over 20% of Galleri volume representing repeat testing. As of March 31, 2025, over 325,000 Galleri tests had been prescribed by more than 14,000 healthcare providers since its commercial launch in 2021, with more than 37,000 tests sold in Q1 2025. The growing demand for early cancer detection presents significant opportunities for GRAIL Inc to expand its market presence.

GRAIL, Inc. is a healthcare and biotechnology company focused on early cancer detection, founded in 2015. Its mission is to reduce cancer mortality by making multi-cancer early detection a routine part of medical care. GRAIL operates in the diagnostics and precision medicine sectors, utilizing machine learning, AI, and genomic sequencing to develop blood-based tests for early cancer detection. Its flagship product is Galleri, a multi-cancer early detection blood test for asymptomatic individuals over 50, screening for over 50 cancer types. The company also offers DAC, a diagnostic aid for cancer tests, and is developing minimal residual disease and other post-diagnostic tests.

GRAIL, Inc. is headquartered in Menlo Park, California, and provides multi-cancer early detection testing and services in the United States and internationally.

GRAIL's brand reputation has faced both positive and negative impacts. While the Galleri test is promoted as a groundbreaking advance, early trials had "poor" results, and a large-scale NHS England trial was described as "overhyped and unethical". As of 2024, GRAIL was facing "discontent and legal action from investors". Despite these challenges, GRAIL's innovative multi-cancer early detection test positions the company at the forefront of healthcare technology, supported by a robust clinical development program and collaborations with leading healthcare institutions.

Specific details about major institutional and individual owners of GRAIL, Inc. are not available in the provided search results. Illumina, Inc. bought GRAIL outright in 2021 but was ordered by EU regulators to spin it out, a process completed on June 24, 2024.